Basilea Pharmaceutica AG (0QNA) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the Basilea Pharmaceutica Half Year Results twenty twenty six Conference Call and Live Webcast. I am Atel, the Chorus Call operator. I would like to remind you that all participants will be in listen only mode and the conference is being recorded. The presentation will be followed by a Q and A session. The conference must not be recorded for publication or broadcast. At this time it's my pleasure to hand over to David Chief Executive Officer. Please go ahead. Thank you. Hello. I'm David Leach, CEO of Basilea. Thank you for joining us today on our conference call and webcast. We'll be reviewing our financial results and key achievements for the first half year twenty twenty six as well as highlighting our priorities going forward. For further detailed information please see the ad hoc announcement issued this morning and our half year report. These documents together with the webcast presentation are all available on our website at basilea.com. I would like to mention that this call contains forward looking statements. Joining me on our call today are Odesh Kao, our Chief Financial Officer and Doctor Mark Engelhardt, our Chief Medical Officer. We've had a great start to the year, delivering strong financial results and continued execution across the business. Let me briefly summarize some of the key highlights from the first half of twenty twenty six. Starting with our strong financial performance. Basilea's total revenue grew 14% year on year to CHF119 million resulting in an operating profit of CHF32 million, an increase of 32% year on year. Our net cash position doubled to CHF105 million. During the first six months of twenty twenty six we were awarded $61,000,000 of non dilutive funding which offsets a significant proportion of our...